Economic Impact of 4KScore Test

Evaluation of prostate cancer risk using PSA has resulted in many unnecessary prostate biopsies with their attendant complications, follow up tests, and treatments, many of which are done on men with indolent or no prostate cancer. In a clinical utility study, the use of the 4Kscore Test after an abnormal PSA and/or DRE led to a 64.6% reduction in prostate biopsies, with a 94% reduction in low risk men.[1] Utilization of the 4Kscore Test can reduce the costs associated with prostate cancer evaluation and treatment for health plans and employer groups by a significant amount, while continuing to identify men at a higher risk of aggressive prostate cancer for further evaluation.

Ready to learn more?
Click here to contact us for a custom cost-saving analysis for your organization and see how the 4Kscore Test can increase your return on investment.

Learn how the 4Kscore measures a patient’s risk for aggressive prostate cancer

References
1. Konety, B., Zappala, S., Parekh, D., et al. “The 4Kscore® Test Reduces Prostate Biopsy Rates in Community and Academic Urology Practices.” Reviews in urology 17.4 (2015): 231.